|The CCR7 ccr7 (Catalog #MBS5305408) is an Antibody produced from Rat and is intended for research purposes only. The product is available for immediate purchase. The Rat monoclonal CCR7 antibody reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s CCR7 can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS), Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB).
FC: <= 0.5 ug/test. Researchers should empirically determine the suitability of the CCR7 ccr7 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CCR7 ccr7 product has the following accession number(s) (GI #958598315) (NCBI Accession #JAO59341.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Assay Information: A test is defined as the amount (ug) of antibody that will stain a cell sample in a final volume of 100 ul. Cell number should be determined empirically but can range from 10? to 10? cells/test. It is recommended that the antibody be carefully titrated for optimal /formance in the assay of interest. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CCR7 are readily searchable from our website. Different antibodies against the same target such as CCR7 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.